# US 2020/0206133 A1 · Novel pharmaceutical compositions for basic or neutral, low molecular weight compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0206133 A1
- Document ID: US20200206133A1
- Status: Published application
- Kind: A1
- Application number: 16/791,230
- Filed: 2020-02-14
- Published: 2020-07-02
- Earliest claimed: 2017-08-17
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Jochem ALSENZ; Martin KUENTZ; Alfred ROSS; Wiebke Svea SAAL; Nicole WYTTENBACH
- Web page: https://patentgrep.com/patent/US20200206133A1

## CPC

- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/146: {with organic macromolecular compounds}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/4422: 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/593: {Polyesters, e.g. PLGA or polylactide-co-glycolide}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides novel, solid or liquid pharmaceutical preparations comprising a basic or neutral, low molecular weight active pharmaceutical ingredient and the polymer Eudragit® EPO, optionally together with additional pharmaceutically acceptable excipients. The present preparations are for oral or topical administration.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11

A pharmaceutical preparation, comprising a lipophilic, basic or neutral, low molecular weight active pharmaceutical ingredient, and EPO, wherein the pharmaceutical preparation is solid or liquid.

### Claim 12 (depends on 11)

The pharmaceutical preparation of claim 11, further comprising one or more additional pharmaceutically acceptable excipients.

### Claim 13 (depends on 11)

The pharmaceutical preparation of claim 11, wherein the pharmaceutical preparation is a liquid, aqueous solution.

### Claim 14 (depends on 13)

The pharmaceutical preparation of claim 13, wherein the pharmaceutical preparation has a pH from 4.0 to 7.0.

### Claim 15 (depends on 11)

The pharmaceutical preparation of claim 11, wherein the pharmaceutical preparation consists essentially of the lipophilic, basic or neutral, low molecular weight active pharmaceutical ingredient, and EPO.

### Claim 16 (depends on 11)

The pharmaceutical preparation according to claim 11, wherein the low molecular weight active pharmaceutical ingredient is present in an amount from 0.000001% (w/w) to 20% (w/w), and the EPO is present in an amount from 0.01% (w/w) to 20% (w/w).

### Claim 17 (depends on 15)

The pharmaceutical preparation according to claim 15, wherein the low molecular weight active pharmaceutical ingredient is present in an amount from 0.000001% (w/w) to 20% (w/w), and the EPO is present in an amount from 0.01% (w/w) to 20% (w/w).

### Claim 18 (depends on 11)

The pharmaceutical preparation according to claim 11, wherein the lipophilic low molecular weight active pharmaceutical ingredient is basic and positively charged.

### Claim 19 (depends on 15)

The pharmaceutical preparation according to claim 15, wherein the lipophilic low molecular weight active pharmaceutical ingredient is basic and positively charged.

### Claim 20 (depends on 11)

The pharmaceutical preparation according to claim 11, wherein the lipophilic low molecular weight active pharmaceutical ingredient is neutral and without charge.

### Claim 21 (depends on 16)

The pharmaceutical preparation according to claim 16, wherein the lipophilic low molecular weight active pharmaceutical ingredient is neutral and without charge.

### Claim 22 (depends on 11)

A method of treating a patient, comprising administering to the patient a pharmaceutical preparation according to claim 11.

### Claim 23 (depends on 22)

The method of claim 22, wherein the pharmaceutical preparation is administered orally or topically.

### Claim 24 (depends on 11)

A kit, comprising the pharmaceutical preparation according to claim 11, and instructions for how to prepare and administer the pharmaceutical preparation to a patient in need thereof.
